This article is more than 5 years old. Information may no longer be current.
FDA approves meningococcal vaccine for infants as young as 9 months
Click Here to Manage Email Alerts
The FDA has approved a vaccine for the prevention of invasive meningococcal disease caused by certain serogroups of Neisseria meningitidis for use in children, according to a press release from the FDA.
Menactra (Sanofi Pasteur) was approved to prevent N. meningitidis serogroups A, C, Y and W-135. The approval is for a two-dose series beginning at aged 9 months. Doses should be administered three months apart.
The approval came on the heels of results from four trials involving more than 3,700 participants as young as 9 months. Injection-site tenderness and irritability were reported, and fever rates were comparable to other vaccines.
The vaccine is currently approved for use in individuals aged 2 to 55 years.
For more information please visit the FDA website.
 |
Follow the PediatricSuperSite.com on Twitter. |